Adjuvant colon cancer chemotherapy: where we are and where we'll go

被引:71
作者
Lombardi, L. [1 ]
Morelli, F. [1 ]
Cinieri, S. [2 ]
Santini, D. [3 ]
Silvestris, N. [4 ]
Fazio, N. [5 ]
Orlando, L. [2 ]
Tonini, G. [3 ]
Colucci, G. [4 ]
Maiello, E. [1 ]
机构
[1] IRCCS Casa Sollievo Sofferenza, Med Oncol Unit, I-71013 San Giovanni Rotondo, FG, Italy
[2] Hosp Perrino, Med Oncol Unit, Brindisi, Italy
[3] Univ Campus Biomed, Med Oncol Unit, Rome, Italy
[4] Canc Inst Giovanni Paolo II, Med & Expt Oncol Unit, Bari, Italy
[5] Ist Europeo Oncol, Med Oncol Unit, Milan, Italy
关键词
Adjuvant chemotherapy; Colon cancer; Trial; Molecular markers; DISEASE-FREE SURVIVAL; MICROSATELLITE-INSTABILITY STATUS; STAGE-II; COLORECTAL-CANCER; MISMATCH-REPAIR; PLUS LEUCOVORIN; FLUOROURACIL; THERAPY; OXALIPLATIN; IRINOTECAN;
D O I
10.1016/S0305-7372(10)70018-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Many patients with early-stage colon cancer are cured with surgery alone, even if the standard of care remains an uniform approach to adjuvant chemotherapy based primarily on tumour stage. Consequently, it is important to individualize decision-making in this subset of patients with the aim to identify potential prognostic and predictive markers in colon cancer. While 5-fluorouracil, leucovorin, and oxaliplatin are widely known as gold treatment in the post-operative of stage III, well-validated molecular markers might help define which patients with stage II disease are likely to benefit from adjuvant therapy as well. Herein we review the use of adjuvant chemotherapy in colon cancer and analyzed the date on the clinical development of molecular markers to individualize another therapeutic approach in colon cancer. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:S34 / S41
页数:8
相关论文
共 50 条
  • [21] Age Determines Adjuvant Chemotherapy Use in Resected Stage II Colon Cancer
    Hagerty, Brendan L.
    Aversa, John G.
    Dominguez, Dana A.
    Davis, Jeremy L.
    Hernandez, Jonathan M.
    McCormick, James T.
    Blakely, Andrew M.
    [J]. DISEASES OF THE COLON & RECTUM, 2022, 65 (10) : 1206 - 1214
  • [22] Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
    Chen, Xin
    Tu, Junhao
    Xu, Xiaolan
    Gu, Wen
    Qin, Lei
    Qian, Haixin
    Jia, Zhenyu
    Ma, Chuntao
    Xu, Yinkai
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [23] The Role of the Gut Microbiome in Colorectal Cancer: Where Are We? Where Are We Going?
    Wieczorska, Karina
    Stolarek, Malgorzata
    Stec, Rafal
    [J]. CLINICAL COLORECTAL CANCER, 2020, 19 (01) : 5 - 12
  • [24] Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer
    Koenig, Julie L.
    Toesca, Diego A. S.
    Harris, Jeremy P.
    Tsai, Chiaojung Jillian
    Haraldsdottir, Sigurdis
    Lin, Albert Y.
    Pollon, Erqi L.
    Chang, Daniel T.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (07): : 573 - 580
  • [25] Reasons for Delay in Time to Initiation of Adjuvant Chemotherapy for Colon Cancer
    Wasserman, David W.
    Boulos, Majdi
    Hopman, Wilma M.
    Booth, Christopher M.
    Goodwin, Rachel
    Biagi, James J.
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2015, 11 (01) : E28 - E35
  • [26] Adjuvant Chemotherapy for Stage II Colon Cancer
    Rebuzzi, Sara Elena
    Pesola, Guido
    Martelli, Valentino
    Sobrero, Alberto Felice
    [J]. CANCERS, 2020, 12 (09) : 1 - 12
  • [27] Locally Advanced Pancreatic Adenocarcinoma: Where Are We and Where Are We Going?
    Chang, Bryan W.
    Saif, Muhammad Wasif
    [J]. JOURNAL OF THE PANCREAS, 2011, 12 (02): : 101 - 105
  • [28] Cancer treatment data available in European cancer registries: Where are we and where are we going?
    Giusti, Francesco
    Martos, Carmen
    Trama, Annalisa
    Bettio, Manola
    Sanvisens, Arantza
    Audisio, Riccardo
    Arndt, Volker
    Francisci, Silvia
    Dochez, Carine
    Ribes, Josepa
    Pareja Fernandez, Laura
    Gavin, Anna
    Gatta, Gemma
    Marcos-Gragera, Rafael
    Lievens, Yolande
    Allemani, Claudia
    De Angelis, Roberta
    Visser, Otto
    Van Eycken, Liesbet
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] Molecular therapies of colorectal cancer: Where will we go from here?
    Prager G.
    [J]. memo - Magazine of European Medical Oncology, 2013, 6 (3) : 215 - 219
  • [30] Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?
    Roda, Desamparados
    Ciardiello, Fortunato
    Cervantes, Andres
    [J]. ESMO OPEN, 2018, 3 (04)